Massachusetts governor warns healthcare execs to be realistic about AI

Massachusetts Gov. Charlie Baker issued a piece of cautionary advice to healthcare executives April 8, urging them to take the recent rise of AI with a grain of salt, the Boston Business Journal reported.

Baker, a former health insurance executive and health and human services chief under Gov. William Weld, warned attendees of the Partners HealthCare World Medical Innovation Forum in Boston that while AI can certainly contribute to better health outcomes, researchers need to be careful in the way they roll out the tech.

“My advice is to recognize and understand the people in healthcare get held to a higher standard,” he said. “That’s just the way it is. And that’s not a bad thing, because people believe in you and what you’re capable of and what you can do.”

The process of developing reputable, reliable AI could suffer under that microscope. Baker, who’s familiar with the investment side of AI, said innovators are eager to get their solutions to market but are often unable to deliver solid results in the timeframe they predicted.

Baker said he’s a “big believer in the deployment of technology,” but warned researchers to be realistic about both the capabilities of their innovations and their potential shortcomings.

“I just hope I’m alive long enough to benefit from your ability to deploy all this stuff, to deliver higher outcomes, better results for really complicated people who are dealing with really difficult things,” he said.

Read the full story below:

""

After graduating from Indiana University-Bloomington with a bachelor’s in journalism, Anicka joined TriMed’s Chicago team in 2017 covering cardiology. Close to her heart is long-form journalism, Pilot G-2 pens, dark chocolate and her dog Harper Lee.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.